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Abstract: Angiogenesis, the formation of new blood vessels, is an essential component of 
glioblastoma (GB) progression. The development of angiogenesis inhibitor therapy, including 
treatments targeting vascular endothelial growth factor (VEGF) in particular, raised new hopes 
for the treatment of GB, but no Phase III clinical trial to date has reported survival benefits rela-
tive to standard treatment. There are several possible reasons for this limited efficacy, including 
VEGF-independent angiogenesis, induction of tumor invasion, and inefficient antiangiogenic 
factor delivery to the tumor. Efforts have been made to overcome these limitations by identifying 
new angiogenesis inhibitors that target angiogenesis through different mechanisms of action 
without inducing tumor invasion, and through the development of viral and nonviral delivery 
methods to improve antiangiogenic activity. Herein, we describe the nonviral methods, includ-
ing convection-enhanced delivery devices, implantable polymer devices, nanocarriers, and 
cellular vehicles, to deliver antiangiogenic factors. We focus on those evaluated in intracranial 
(orthotopic) animal models of GB, the most relevant models of this disease, as they reproduce 
the clinical scenario of tumor progression and therapy response encountered in GB patients.
Keywords: antiangiogenic factors, delivery methods, glioblastoma, convection-enhanced 
delivery devices, implantable polymer devices, nanocarriers, cellular vehicles
Introduction
Glioblastoma (GB) is the commonest and most aggressive primary brain tumor. 
Despite standard treatment including resection and radiotherapy plus concomitant 
and adjuvant temozolomide (TMZ), prognosis remains poor, with a median survival 
of 12–18 months after diagnosis.1,2
GB is highly invasive and is characterized by a high rate of cell proliferation, heteroge-
neity, necrosis, and an abnormal angiogenic vasculature. This abnormal vasculature con-
tributes to the development of high interstitial fluid pressure within the tumor, preventing 
the effective delivery of chemotherapy agents to the tumor tissue. This dysfunctional vas-
culature can also hinder tumor oxygenation, thereby promoting resistance to radiotherapy.3
This key role of the vasculature in treatment resistance has led to interest in GB 
treatment strategies that interfere with angiogenesis or destroy the existing tumor 
blood vessel network. The vascular abnormalities observed in GB have been attrib-
uted principally to the very high levels of vascular endothelial growth factor (VEGF) 
produced by tumor cells and tumor-associated stromal and inflammatory cells. VEGF 
is an angiogenic mitogen that operates by binding to VEGF receptors, triggering endo-
thelial cell proliferation, migration, and the formation of new vessels. The possibility 
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of blocking this key process with angiogenesis inhibitors 
has raised hopes that it might be possible to inhibit tumor 
growth, thereby prolonging patient survival. However, 
Phase III clinical trials involving the systemic administration 
of the anti-VEGF-A antibody bevacizumab (Avastin) or a 
pan-VEGF receptor (VEGFR)-2 tyrosine kinase inhibitor 
(cediranib, Recentin) in patients with recurrent or newly 
diagnosed GB have yielded disappointing results.4,5 These 
agents alleviated symptoms and made it possible to reduce 
steroid dose, but no improvement in overall survival rela-
tive to standard treatment was observed. There are several 
possible reasons for this limited efficacy, including VEGF-
independent angiogenesis, induction of tumor invasion, and 
inefficient antiangiogenic factor delivery to the tumor.
These limitations have led to an intensification of efforts 
to discover new angiogenesis inhibitors targeting this pro-
cess via more than one mechanism without inducing tumor 
invasion, and efforts to develop viral and nonviral delivery 
methods for local or systemic treatment to improve antian-
giogenic activity. Many studies have evaluated these methods 
in subcutaneous (heterotopic) models of GB. However, these 
models do not take into account tissue-specific constraints, 
such as the effects of the blood–brain barrier (BBB) and the 
brain microenvironment associated with GB therapy. Studies 
in such models may, therefore, lead to an overinterpretation of 
the effects of the engineered delivery methods.6 In this review, 
we present the local or systemic nonviral delivery methods 
used to increase the activity of antiangiogenic factors, focus-
ing in particular on those evaluated in intracranial (orthotopic) 
animal models of GB, which are the most relevant, as they 
closely resemble the human disease in terms of the clinical 
scenario of tumor progression and treatment response.
Angiogenesis and GB
The tumor requires new blood vessels to provide it with 
oxygen and nutrients once its volume increases beyond 
1–2 mm3.7 Angiogenesis increases the blood supply to the 
tumor through the development of new vessels from the pre-
existing vasculature (Figure 1). This process is regulated by 
the balance between proangiogenic factors, such as VEGF 
Figure 1 Angiogenesis and GB.
Note: Five mechanisms are used to increase blood supply to the tumor: angiogenesis, vessel co-option, intussusception, vascular mimicry, and bone marrow-derived vasculogenesis.
Abbreviations: ePCs, endothelial progenitor cells; GB, glioblastoma; GSCs, glioblastoma stem-like cells; HSCs, hematopoietic stem cells; MSCs, mesenchymal stem cells 
or mesenchymal stromal cells.
$QJLRJHQHVLV භ
3URDQJLRJHQLFIDFWRUV 9HVVHOFRRSWLRQභ
,QWXVVXVFHSWLRQභ භ 9DVFXODUPLPLFU\
3HULF\WHV
*6&V
භ %RQHPDUURZGHULYHGYDVFXORJHQHVLV
3HULF\WHV %RQHPDUURZGHULYHGFHOOV(3&V06&V+6&V
(QGRWKHOLDOFHOOV
(QGRWKHOLDOFHOOV
7XPRUYHVVHO
7XPRUYHVVHO
0RGHVRIWXPRUEORRGVXSSO\
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
52
.4
0.
1 
on
 0
9-
M
ay
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2019:14 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2499
Clavreul et al
and fibroblast growth factor-2 (FGF-2), and antiangiogenic 
factors, such as angiostatin, angiopoietin 2, and endostatin. 
These factors may be released by the tumor itself or by 
the surrounding tissues. The blood supply may also be 
increased by vascular co-option, vascular intussusception, 
vasculogenic mimicry, and bone marrow-derived vasculo-
genesis (Figure 1).8–11 Briefly, vascular co-option involves 
the infiltration of tumor cells into normal tissue and adoption 
of the pre-existing vasculature. Vessel intussusception is the 
formation of new vessels by the enlargement and bifurcation 
of existing vessels. Vasculogenic mimicry is a process in 
which GB stem-like cells (GSCs) contribute to the formation 
of tumor blood vessels by differentiating into endothelial cells 
or pericytes. Bone marrow-derived vasculogenesis involves 
the recruitment of endothelial progenitor cells (EPCs), mes-
enchymal stem cells (MSCs), or hematopoietic stem cells 
to the tumor, their integration into the vessel wall, and their 
terminal differentiation into endothelial cells (Figure 1).
The new tumor vasculature is leaky, circuitous, dilated, 
and saccular, with a haphazard pattern of interconnection.12,13 
In particular, the endothelial cells lining the new vessels have 
an irregular, disorganized morphology and are often poorly 
connected or overlap. The cells supporting the endothelial 
cells, the pericytes, are loosely attached or absent, and the 
basement membrane may be abnormally thick or entirely 
absent. The physiological consequences of these vascular 
abnormalities include temporal and spatial heterogeneity 
in tumor blood flow and oxygenation and an increase in 
tumor interstitial fluid pressure. These abnormalities and 
the microenvironment they create fuel tumor progression 
and decrease the efficacy of chemotherapy, radiotherapy, 
and immunotherapy.12,13
Antiangiogenic factors and GB
Given the importance of angiogenesis in GB progression 
and resistance to treatment, efforts have been made to 
develop novel therapies based on antiangiogenic factors, 
to achieve tumor regression through starvation. A number 
of angiogenesis inhibitors have been shown to affect the 
growth of various tumors, including GB, and this list is 
continuing to grow. These inhibitors can be classified into 
four categories (Figure 2).
endogenous antiangiogenic factors
Endogenous antiangiogenic factors are molecules with 
antiangiogenic activity naturally present in body fluids or 
tissues.14 They are highly attractive candidate drugs because 
they are relatively non-toxic and well tolerated, with a low 
risk of drug resistance. They exert their effects through 
multiple mechanisms, including the induction of endothe-
lial cell apoptosis, inhibition of endothelial cell migration 
to sites of neovascularization, inhibition of proangiogenic 
molecules, and changes to the regulation of proangiogenic 
and antiangiogenic molecules. Some endogenous antian-
giogenic factors are secreted by specific cells in different 
organs. These factors include pigment epithelium-derived 
factor (PEDF), platelet factor-4 (PF-4), thrombospondin 
(TSP)-1 and -2, and several members of the interleukin 
(IL) and interferon (IFN) families, such as IL-4, IL-12, and 
IFN-β. Others are created by the extracellular proteolytic 
cleavage of plasma-derived or extracellular matrix proteins, 
such as angiostatin (fragment of plasminogen), endostatin 
(fragment of collagen XVIII), PEX (fragment of matrix 
metalloproteinase-2 [MMP-2]), and vastatin (fragment 
of collagen VIII). MicroRNAs have also been identified 
Figure 2 Antiangiogenic factors and GB.
Note: Four categories of angiogenesis inhibitors are used in clinical trials for GB: endogenous factors, monoclonal antibodies, tyrosine kinase inhibitors, and other factors.
Abbreviations: GB, glioblastoma; HeR2, eGF-related receptor 2; IFN, interferon; MeT, hepatocyte growth factor receptor; PeX, fragment of matrix metalloproteinase-2; 
PF-4, platelet factor-4; TSP, thrombospondin.
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as a new class of endogenous angiogenesis inhibitors. 
For example, microRNA-16 plays a crucial role in repress-
ing endothelial function and angiogenesis in GB.15 The 
efficacy of angiostatin, endostatin, PEX, PEDF, and TSP-1 
and -2 has been studied in experimental models of malignant 
gliomas.16,17 However, most of these molecules have not yet 
been through clinical trials. A Phase I trial was performed 
to determine the maximum tolerated dose of ABT-510, 
a TSP-1 mimetic drug, used concomitantly with TMZ and 
radiotherapy in patients with newly diagnosed GB.18 The 
addition of ABT-510 to TMZ and radiotherapy was well tol-
erated by patients with GB, without unexpected adverse or 
serious adverse events. Progression-free and overall survival 
results were encouraging in light of historical expectations, 
but no Phase II trial was conducted.
Antiangiogenic monoclonal antibodies
Antibodies are key immune system components providing 
protection against infection. Antibodies directed against 
proangiogenic signaling proteins have been produced and 
shown to have antitumor activity in preclinical and clinical 
trials.19 Bevacizumab (Avastin), a recombinant humanized 
monoclonal antibody that targets VEGF-A, has been exten-
sively studied in GB. However, Phase III trials showed that 
although the addition of bevacizumab to the standard treat-
ment for newly diagnosed GB prolonged progression-free 
survival and improved the performance status of patients, it 
did not increase overall survival.20,21 Onartuzumab, a human-
ized monovalent monoclonal antibody against c-Met (or 
hepatocyte growth factor receptor [HGFR]) was recently 
evaluated in combination with bevacizumab in patients with 
recurrent GB.22 This antibody inhibits HGF binding and 
abolishes the ligand-induced phosphorylation of c-Met. How-
ever, no evidence of further clinical benefit was observed in 
comparisons of onartuzumab plus bevacizumab with bevaci-
zumab plus placebo in unselected patients with recurrent GB. 
Nevertheless, exploratory biomarker analyses have suggested 
that patients with tumors displaying high levels of HGF or 
unmethylated O6-methylguanine-DNA methyltransferase 
expression may benefit from treatment with a combination of 
these two antibodies. Phase I/II trials with three other mono-
clonal antibodies (cetuximab [anti-epidermal growth factor 
receptor (EGFR), Erbitux], tanibirumab [TTAC-0001, anti-
VEGR2], and TRC105 [carotuximab, anti-CD105]) either 
as single agents or in combination with bevacizumab have 
either recently been completed or are currently underway 
in patients with recurrent GB (https://ClinicalTrials.gov).
Antiangiogenic tyrosine kinase  
inhibitors (TKIs)
TKIs have been developed and clinical trials have been 
performed to assess their ability to block the specific tyrosine 
phosphorylation (activation) of a panel of angiogenic cell-
surface tyrosine kinase receptors, such as VEGFR, bFGFR, 
platelet-derived growth factor receptor (PDGFR), EGFR, and 
their downstream intracellular serine/threonine kinases.23 Many 
of these TKIs are described as “multi-targeted kinase inhibi-
tors” because they target several different kinases. A number 
of TKIs are being studied in Phase I/II clinical trials in patients 
with GB24 (Figure 2). To date, limited clinical benefit has been 
reported following treatment with TKIs in monotherapy or in 
combination with other approaches for the treatment of GB.24
Other antiangiogenic factors
Other antiangiogenic factors have been developed, including 
VEGF-Trap (afibercept), a soluble VEGF receptor; AMG 
386 (trebananib), which binds angiopoietins Ang1 and 
Ang2; and cilengitide, a potent αvβ3 and αvβ5 integrin antag-
onist. However, no improvement was observed in patients 
with GB treated with these factors in clinical trials.25–27
effects of antiangiogenic factors on the 
tumor vasculature
Antiangiogenic agents are thought to have a direct effect 
on the tumor vasculature. This effect involves endothelial 
cell apoptosis and ultimately leads to a cytostatic effect on 
new blood vessel growth and a decrease in tumor perfusion 
(Figure 3). These effects restrict the supply of oxygen and 
nutrients to the tumor, causing “tumor starvation”.7 However, 
it has also been suggested that antiangiogenic agents achieve 
their antitumor effects by vascular normalization, decreas-
ing the permeability and diameter of blood vessels, thereby 
increasing tumor perfusion, decreasing interstitial pressure, 
and promoting tumor oxygenation (Figure 3). Such conditions 
sensitize the tumor to radiotherapy and increase the expo-
sure of the tumor to cytotoxic drugs during chemotherapy.28 
Antiangiogenic agents may also be active against GSCs29–31 
and may disrupt proangiogenic signaling from bone marrow-
derived cells, thereby abolishing tumor vascularization.32
Nonviral delivery methods for 
antiangiogenic factors
Many antiangiogenic factors have been discovered, but, 
like other anticancer drugs, all face challenges to their use 
in GB therapy. In particular, most antiangiogenic factors 
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cannot cross the BBB, and do not, therefore, reach therapeu-
tic concentrations in the brain. In GB, the BBB is partially 
disrupted in the tumor core, but is mostly intact, forming a 
strong barrier protecting the tumor from the external envi-
ronment. High systemic levels of antiangiogenic factors are, 
therefore, required to achieve effective concentrations within 
the tumor. However, increases in the dose of antiangiogenic 
agent, or in the frequency and duration of treatment, are 
often limited by systemic toxicity. For example, the systemic 
administration of antiangiogenic agents targeting the VEGF 
pathway has been associated with diverse adverse effects, 
including cardiovascular and renal complications, hemor-
rhage, wound complications, gastrointestinal perforation, 
and reversible posterior leukoencephalopathy syndrome.33 
For these reasons, major efforts are currently being made 
to develop viral and nonviral delivery methods to solve the 
problem of BBB permeability and to reduce the amounts of 
antiangiogenic factor required for treatment, thereby decreas-
ing treatment toxicity and adverse effects. We present four 
main local or systemic nonviral methods for antiangiogenic 
factor delivery that have been evaluated in orthotopic animal 
models of GB: convection-enhanced delivery (CED) devices, 
implantable polymer devices, nanocarriers, and cellular 
vehicles (Figure 4). The principal results obtained for the use 
of these devices alone or in combination with chemotherapy 
or radiotherapy are indicated in Table 1.
CeD devices
In several recent clinical trials on GB, CED has been used 
for administration of anticancer agents directly into the 
tumor with a potential to provide concentrations that cannot 
be achieved with systemic drug delivery.34–37 CED involves 
the surgical implantation of catheters in the tumor itself 
or in the surrounding brain parenchyma. The catheters are 
connected to an infusion pump to create a positive pressure 
gradient at the catheter tip. This allows for safe, targeted, 
and reliable homogeneous delivery of small and large 
molecular weight substances at clinically relevant volumes 
in a manner that bypasses the BBB. The CED of a mixture 
of anticancer agent and a surrogate tracer for imaging can 
now be used to monitor drug distribution in real time by 
computed tomography or magnetic resonance imaging.36 
The preclinical studies performed on animal models in 
which CED was used to administer angiogenesis inhibitors 
are listed in Table 1. The CED devices used were based 
on Alzet osmotic pumps or programmable syringe pumps. 
Diverse antiangiogenic agents or nanocarriers carrying 
antiangiogenic factors have been administered in this way 
Figure 3 effects of antiangiogenic factors on the tumor vasculature.
Notes: (A) The normal vasculature is maintained by the balance of pro- and antiangiogenic factors, which ensure the perfusion of sufficient oxygen and other nutrients to 
all cells. (B) In the tumor, excessive amounts of proangiogenic factors, such as VEGF, are produced, leading to the growth of an abnormal and inefficient vascular network, 
resulting in an impairment of blood flow and resistance to chemotherapy, radiotherapy, and immunotherapy. (C) Antiangiogenic factors are thought to destroy tumor blood 
vessels, eventually starving the tumor to death or inducing its dormancy. It has also been suggested that antiangiogenic factors can normalize vessels, improving tumor blood 
flow and sensitizing the tumor to radiotherapy and chemotherapy. Antiangiogenic factors may also abolish tumor vascularization by disrupting the proangiogenic effects of 
GSCs and bone marrow-derived cells.
Abbreviations: GB, glioblastoma; GSCs, GB stem-like cells.
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in GB-bearing animals: bevacizumab,38 polyplexes (poly-
mer/DNA) encoding a soluble VEGFR-1 (sFlt-1) and an 
angiostatin-endostatin fusion protein (statin-AE),39 siRNA 
targeting hypoxia-inducible factor 1α (HIF-1α),40 the immu-
notoxins, DTAT (diphtheria toxin [DT] targeting urokinase 
plasminogen activator receptor [uPAR]) and DTATEGF 
(DT targeting uPAR and EGFR),41 endostatin or endostatin 
fused to an antibody (IgG) Fc domain (Fc-endostatin),42,43 
two mechanistically different inhibitors of the CYP/CYP450 
2C11 epoxygenase, 17-octadecynoic acid and miconazole,44 
and sorafenib-loaded lipid nanocapsules (SFN-LNCs).45 The 
administration of these agents by CED has frequently been 
shown to lead to a significant decrease in capillary formation 
and tumor size and an increase in animal survival. Wang 
et al38 demonstrated that bevacizumab administered by CED 
resulted in longer animal survival than the same drug admin-
istered intravenously. Furthermore, combining the CED of 
angiogenesis inhibitors (bevacizumab or Fc-endostatin) with 
the systemic administration of chemotherapy agents (CPT-11 
or TMZ) was found to be the most effective approach for 
increasing survival.38,42 One clinical trial of intracerebral infu-
sion by CED was performed with a recombinant toxin, TP-38, 
targeting the EGFR in patients with recurrent GB.46 The CED 
of TP-38 was found to be well tolerated at effective doses 
and encouraging radiographic responses were observed. 
However, this trial also showed that the potential efficacy 
of agents delivered by CED in humans might be limited by 
inconsistent and inefficient infusion in many patients. These 
technical shortcomings will need to be addressed if CED is 
to fulfill its therapeutic potential.34,37
Implantable polymer devices
Implantable polymer devices provide a robust technology 
platform for the local and sustained delivery of drugs 
directly to the tumor.47,48 Gliadel wafers are currently the 
only biodegradable polymer implants for intracranial drug 
delivery approved for GB treatment by the US Food and Drug 
Administration (FDA) and the European Medicines Agency 
Figure 4 Nonviral delivery methods for antiangiogenic factors.
Note: Four main nonviral methods have been developed to deliver angiogenesis inhibitors in orthotopic GB models: CeD devices, implantable biodegradable polymer 
devices, nanocarriers, and cellular vehicles.
Abbreviations: CeD, convection-enhanced delivery; CPP, 1,3-bis[p-carboxyphenoxy] propane; GB, glioblastoma; LNCs, lipid nanocapsules; MSCs, mesenchymal stem cells; 
NSCs, neural stem cells; PLGA, poly([d,l]-lactide-co-glycolide); SA, sebacic acid.
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Table 1 Nonviral antiangiogenic factor delivery methods evaluated in orthotopic GB animal models
Delivery 
method
Antiangiogenic 
factor
Administration GB model Major results Reference
CED devices
Osmotic pump Avastin 
(bevacizumab)
[± CPT-11 (IP)]
IT or Iv Human U87MG/
U251
U251 tumor-bearing mice treated with CeD of 
bevacizumab alone or in combination with CPT-11 
survived longer than those treated systemically:
[U251 tumor alone]: 23 days
[CPT-11]: 24 days
[Avastin_Iv]: 26 days
[Avastin_CeD]: 36 days
[Avastin_Iv + CPT-11]: 33 days
[Avastin_CeD + CPT-11]: 37 days
A similar effect was obtained with the U87MG model
38
Programmable 
syringe pump
Polyplexes:
(sFlt-1/statin-Ae/PeI)
IT Human U87-Luc CeD of sFlt-1/statin-Ae/PeI polyplexes caused complete 
tumor regression: 18% of animals were tumor-free
39
Osmotic pump siRNA targeting 
HIF-1α/PeG
IT Human U87-Luc CeD of siRNA targeting HIF-1α enhanced survival:
[Control PeG-siRNA]: 18 days
[PeG-siRNA1589]: 35 days
40
Osmotic pump Immunotoxins: 
DTAT/DTATeGF
IT Human U87-Luc CeD of DTAT or DTATeGF inhibited the growth 
of U87-Luc GB cells in nude mice and killed small 
solid tumors
41
Osmotic pump endostatin IT Human U87MG CeD of endostatin enhanced survival:
[U87MG tumor alone]: 26 days
[endostatin]: 34 days
43
Programmable 
syringe pump
Fc-endostatin
[± TMZ (O)]
IT Rat 9L CeD of Fc-endostatin enhanced survival, with an even 
greater increase when Fc-endostatin was combined 
with TMZ:
[9L tumor alone]: 13 days
[TMZ]: 21 days
[Fc-endostatin]: 14 days
[Fc-endostatin + TMZ]: 23 days
42
Osmotic pump Inhibitors of CYP 
epoxygenase:
17-ODYA or 
miconazole
IT Rat RG2 CeD of inhibitors of CYP epoxygenase enhanced 
survival:
[RG2 tumor alone]: 17 days
[17-ODYA]: 22 days
[Miconazole]: 23 days
44
Programmable 
syringe pump
SFN-LNCs IT Human U87MG CeD of SFN-LNCs decreased the proportion of 
proliferating cells in the tumor and induced early 
tumor vascular normalization, characterized by 
increases in tumor blood flow and decreases in 
tumor vessel area
45
Two barium-
impregnated 
catheters
TP-38 IT Phase I trial on 
recurrent GB
CeD of TP-38 was well tolerated and produced some 
durable radiographic responses at doses ,100 ng/mL
46
Implantable polymer devices
evAc disk Minocycline
[± BCNU (IP)]
IT Rat 9L Minocycline polymer implantation combined with 
BCNU enhanced survival relative to BCNU alone:
[9L tumor alone]: 13 days
[Minocycline polymer]: 13 days
[BCNU]: 28 days
[Minocycline polymer + BCNU]: 55 days
57
CPP-SA wafer Minocycline
[± BCNU (IP)]
IT Rat 9L Minocycline polymer implantation enhanced survival, 
with even greater effects when minocycline was 
combined with BCNU:
[9L tumor alone]: 14 days
56
(Continued)
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Table 1 (Continued)
Delivery 
method
Antiangiogenic 
factor
Administration GB model Major results Reference
[Minocycline polymer]: 19 days
[BCNU]: 24 days
[Minocycline polymer + BCNU]: 42 days
CPP-SA wafer Minocycline
[± TMZ (O) or RT]
IT Rat 9L Minocycline delivered locally potentiated the effects 
of both radiotherapy and oral TMZ, increasing 
median survival in 9L tumor-bearing rats:
[9L tumor alone]: 14 days
[TMZ]: 21 days
[RT]: 31 days; 6.7% long-term survivors
[Minocycline polymer]: 19 days
[Minocycline polymer + TMZ]: 29 days; 6.3% 
long-term survivors
[Minocycline polymer + RT]: 74 days; 46.7% 
long-term survivors
55
CPP-SA wafer Fc-endostatin
[± TMZ (O)]
IT Rat 9L Fc-endostatin polymer implantation enhanced 
survival; which was increased still further by the 
combination of Fc-endostatin with TMZ:
[9L tumor alone]: 13 days
[TMZ]: 21 days
[Fc-endostatin polymer]: 15 days
[Fc-endostatin polymer + TMZ]: 28 days
42
PLGA 
nanofibrous 
membrane
PTX/siRNA 
targeting MMP-2
IT Human 
U87MG-Luc2
The PTX/siRNA dual implant significantly enhanced 
tumor growth inhibition, by a factor of about 
30 relative to PTX implant only
63
PLGA 
nanofibrous 
membrane
BIC + combretastatin 
(BICC)
IT Rat C6 BICC/PLGA nanofibrous membrane implantation 
enhanced survival:
[C6 tumor alone]: 23 days
[BIC/PLGA]: 60 days
[BICC/PLGA]: 87 days
64
PLGA 
microspheres
PF-4/CTF IT Human U87MG A single injection of microspheres containing PF-4/
CTF caused a 65% reduction in tumor volume 
relative to empty microspheres
65
Nanocarriers
Polyplexes sFlt-1/statin-Ae/PeI IT Human U87-Luc CeD of sFlt-1/statin-Ae/PeI polyplexes caused 
complete tumor regression: 18% of animals were 
tumor-free
39
Polyplexes IL-12/PPC
[± BCNU wafer]
IT Mouse GL261 Local delivery of IL-12/PPC polyplexes enhanced 
survival, which was increased still further by 
combining pmIL-12/PPC with BCNU:
[GL261 tumor alone]: 45 days
[IL-12/PPC]: 57 days; 25% long-term survivors
[BCNU]: 75% long-term survival
[IL-12/PPC + BCNU]: 100% long-term survivors
76
Polyplexes vastatin or 
endostatin/folate-
PeI600-CyD (H1)
[± TMZ (IP)]
IT Human U87MG/
U87MG-ATR
Local delivery of vastatin or endostatin/H1 enhanced 
survival of U87MG tumor-bearing mice:
[U87MG tumor alone]: 48 days
[Control DNA/H1]: 51 days
[vastatin/H1]: 75 days
[endostatin/H1]: 64 days
Local delivery of vastatin/H1 synergized with TMZ 
and restored the sensitivity of chemoresistant 
U87MG-ATR-bearing mice to TMZ treatments:
[U87-ATR tumor alone]: 25 days
[Control DNA/H1]: 23 days
75
(Continued)
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Table 1 (Continued)
Delivery 
method
Antiangiogenic 
factor
Administration GB model Major results Reference
[TMZ]: 29 days
[vastatin/H1]: 34 days
[vastatin/H1 + TMZ]: 54 days
LNCs SFN IT Human U87MG CeD of SFN-LNCs decreased the proportion of 
proliferating cells in the tumor and induced early 
tumor vascular normalization, characterized by 
increases in tumor blood flow and decreases in 
tumor vessel area
45
Cellular vehicles
Microencapsulated cells
Human fetal 
kidney 293 
cells/alginate 
microcapsules
endostatin IT Rat BT4C Mice orthotopically implanted with a mixture of 
tumor cells and endostatin bioreactors displayed 
enhanced survival:
[BT4C tumor alone]: 22 days
[endostatin bioreactors]: 40 days; 30% long-term 
survivors
82
Human fetal 
kidney 293 
cells/alginate 
microcapsules
endostatin IT Rat C6 endostatin bioreactors inhibited tumor cell invasion 
and reduced the functionality and diameters of the 
tumor-associated microvessels
83, 84
Adult stem cells
NSCs
Mouse NSCs IL-12 IT Mouse GL26 Intratumoral injection of IL-12-producing NSCs 
prolonged survival and induced long-term immunity.
[GL26 tumor alone]: 35 days
[NSC-Control]: 35 days
[NSC-IL-12]: 49 days; 30% long-term survivors
88
Human NSCs IL-12 IT Rat C6 Intratumoral injection with IL-12-secreting NSCs 
prolonged survival:
[C6 tumor alone]: 17 days
[NSC-IL-12]: 73 days; 50% long-term survivors
93
Human NSCs TSP-1 IT Human Gli36-
eGFRvIII-FD
Intratumoral injection of TSP-1-producing NSCs 
prolonged survival:
[NSC-Control]: 23 days
[NSC-IL-12]: 29 days
92
Mouse NSCs endostatin IT Mouse GL261 Intratumoral injection of endostatin-producing NSCs 
caused a 65% reduction in tumor size relative to the 
injection of control NSCs
90
Human NSCs PeX IT Human U87MG Intratumoral injection of PeX-producing NSCs 
caused a 82% reduction in tumor size relative to the 
injection of control NSCs
89
MSCs
Human MSCs endostatin ± sCe2
[± CPT-11 (Iv)]
IT Human U87MG-
eGFRvIII
Delivery of endostatin and sCe2 by MSCs at the 
tumor sites, along with CPT-11 treatment, resulted in 
reliable antitumor effects in U87MG-eGFRvIII-driven 
orthotopic brain tumor and postsurgery tumor 
recurrence models
94
Human MSCs TSP-1 (3TSR) ± 
sTRAIL
IT Human LN229-
Fluc-mCherry
Intratumoral injection of 3TSR/sTRAIL-producing 
MSCs prolonged survival:
[MSC-Control]: 38 days
[MSC-3TSR]: 45 days
[MSC-sTRAIL]: 55 days
[MSC-3TSR/sTRAIL]: 68 days
86
(Continued)
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(EMA).49–51 They are made of a polyanhydride copolymer 
(1,3-bis[p-carboxyphenoxy] propane [CPP] and sebacic 
acid [SA]), loaded with carmustine (1,3-bis[2-chloroethyl]–
1-nitrosourea [BCNU]). Gliadel wafers are implanted in the 
tumor bed after resection. They provide a controlled local 
release of BCNU over a period of 2–4 weeks. This delivery 
system was shown to be superior to the systemic administra-
tion of BCNU in the 9L rat glioma model, and its systemic 
toxicity was limited.52 Clinical studies have reported Gliadel 
wafers to be effective against both newly diagnosed and 
recurrent GB.53 The combination of Gliadel wafers with 
standard radiotherapy plus concurrent and adjuvant TMZ 
has been shown to increase patient survival by 3–4 months 
relative to Gliadel wafers or TMZ alone.54 The antiangio-
genic agent Fc-endostatin has been loaded onto CPP-SA 
wafers, and the intracranial implantation of Fc-endostatin 
wafers was found to prolong survival in 9L tumor-bearing 
rats.42 A similar effect on survival has been reported for the 
CED of Fc-endostatin to the tumor.42 Additional survival 
benefits were observed when the intratumoral delivery of 
Fc-endostatin via CPP-SA wafers or CED was combined with 
the oral chemotherapy agent TMZ42 (Table 1). Minocycline, 
another angiogenesis inhibitor, has also been loaded onto 
CPP-SA wafers, and the intracranial implantation of minocy-
cline wafers potentiated the effects of systemic chemotherapy 
agents (BCNU or TMZ) or radiotherapy, increasing the 
median survival of treated rats55,56 (Table 1). Weingart et al57 
incorporated minocycline into ethylene-vinyl acetate copo-
lymer (EVAc), a non-biodegradable polymer. They found 
that a combination of the local delivery of minocycline from 
EVAc disks and systemic BCNU increased median survival 
by 93% relative to BCNU alone in 9L tumor-bearing rats.
Other studies have used poly([d,l]-lactide-co-glycolide) 
(PLGA) nanofibrous membranes to deliver antiangiogenic 
factors. PLGA, an FDA- and EMA-approved polymer, is 
highly biocompatible and biodegradable, and is one of the 
most attractive polymeric candidates available for the manu-
facture of devices for drug-delivery and tissue-engineering 
applications.58,59 PLGA nanofibrous membranes are thinner 
than Gliadel wafers, can be cut into any size or shape, and 
can conform completely to the shape of the tissue after tumor 
removal.60 Various drugs can be incorporated into these mem-
branes easily, and the use of PLGA nanofibrous membranes 
with different lactic acid/glycolic acid compositions can yield 
different PLGA degradation profiles, making it possible to 
control the sequential elution of drugs and their release at ther-
apeutic doses.61,62 PLGA nanofibrous membranes also provide 
a longer therapeutic period (more than 8 weeks) than Gliadel 
wafers (2–4 weeks), potentially resulting in a higher thera-
peutic efficacy and lower resistance. Lei et al63 incorporated 
paclitaxel (PTX) and polyplexes encoding a siRNA targeting 
MMP-2 into PLGA nanofibrous membranes. MMP-2 is an 
essential proteinase regulating brain tumor invasion and 
angiogenesis. This dual delivery of PTX and MMP-2 siRNA 
Table 1 (Continued)
Delivery 
method
Antiangiogenic 
factor
Administration GB model Major results Reference
Human MSCs IL-12 IT Mouse GL26 Intratumoral injection of IL-12-producing MSCs 
prolonged survival:
[GL26 tumor alone]: 46 days
[MSC-Control]: 51 days
[MSC-IL-12]: 70% long-term survivors
91
Rat MSCs IFN-α IT Rat 9L Rats implanted with a mixture of tumor cells and 
IFN-α-producing MSCs displayed enhanced survival:
[MSC-Control]: 16.5 days
[MSC-IFN-α]: 19 days
87
Human MSCs SFN IN Human U87MG Two intranasal administrations of SFN-primed MSCs 
in U87MG tumor-bearing mice resulted in lower 
levels of tumor angiogenesis than the injection of 
unprimed MSCs or SFN alone but had no effect on 
tumor volume
96
Abbreviations: ATR, acquired TMZ resistance; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; BIC, BCNU-irinotecan-cisplatin; BICC, BIC-combretastatin; CeD, convection-
enhanced delivery; CPP, 1,3-bis-[p-carboxyphenoxy] propane; CPT-11, Camptosar (irinotecan); CYP epoxygenase, cytochrome P450 2C11 epoxygenase; DTAT, diphtheria 
toxin (DT) targeting urokinase plasminogen activator receptor (uPAR); DTATeGF, DT targeting uPAR and eGFR; evAc, ethylene-vinyl acetate copolymer; Fc-endostatin, 
recombinant human endostatin conjugated to the Fc domain of IgG; FD, Fluc-DsRed2; GB, glioblastoma; HIF, hypoxia-inducible factor; IFN, interferon; IL, interleukin; IP, 
intraperitoneal; IT, intratumoral; LNCs, lipid nanocapsules; Luc, luciferase; MMP-2, matrix metalloproteinase-2; MSCs, mesenchymal stromal cells; NSCs, neural stem cells; 
O, oral; 17-ODYA, 17-octadecynoic acid; PeG, polyethylene glycol; PeI, polyethylenimine; PeX, fragment of MMP-2; PF-4/CTF, C-terminal fragment of platelet factor-4; 
PLGA, poly([D,L]-lactide-co-glycolide); PPC, PeI covalently linked to methoxy-polyethyleneglycol and cholesterol functional groups; PTX, paclitaxel; RT, radiotherapy; sCe2, 
secretable form of carboxylesterase 2; sFlt-1, soluble veGFR-1; siRNA, small interfering RNA; SA, sebacic acid; SFN, sorafenib; Statin-Ae, angiostatin-endostatin fusion 
protein; TMZ, temozolomide; TP-38, recombinant toxin targeting eGFR; sTRAIL, secretable variant of tumor necrosis factor-related apoptosis-inducing ligand 1; TSP-1, 
thrombospondin-1; 3TSR, three type-1 repeat domain of TSP-1.
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by PLGA nanofibrous membranes was tested in mice with 
intracranial U87MG-Luc2 xenografts, and was found to 
have a significantly greater therapeutic efficacy than the 
delivery of PTX alone, with the two agents acting in synergy. 
Tseng et al60,64 loaded 50:50 PLGA nanofibers with three 
chemotherapy agents (BCNU, irinotecan, and cisplatin; BIC/
PLGA), and 75:25 PLGA nanofibers with BIC and an anti-
angiogenic agent (combretastatin phosphate, CA4P; BICC/
PLGA). The chemotherapy agents were rapidly released 
from the 50:50 PLGA nanofibers after implantation, and 
combretastatin was released from the 75:25 PLGA nanofibers 
about 2 weeks later. BICC/PLGA nanofibrous membranes 
implanted in the brains of C6 tumor-bearing rats slowed 
tumor growth and decreased malignancy more effectively 
than BIC/PLGA nanofibrous membranes.
One study used PLGA microspheres to deliver an antian-
giogenic factor, C-terminal fragment of PF-4 (PF-4/CTF).65 
This study showed that the intratumoral injection of PF-4/
CTF-loaded microspheres in U87MG tumor-bearing mice 
decreased tumor volume by about 70%, this effect being 
accompanied by a significant decrease in angiogenesis and 
an increase in apoptosis. Microspheres constitute a versatile 
class of drug carriers for which drug release kinetics can be 
controlled by modulating microsphere formulation (size, 
molecular weight, and PLGA composition).66 Due to their 
size and shape, polymeric microspheres are easy to implant 
at the tumor site by stereotactic injection, or to inject into 
the walls of brain tumor resection cavities with a handheld 
syringe during surgery.67
Encouraging results have been obtained with implantable 
polymer devices, but further optimization of these devices 
is required to overcome the specific challenges of localized 
treatment, including sustainable release over a long period 
and deeper tissue penetration.68 Polymeric microreservoirs 
could potentially improve the efficacy of local treatment for 
brain cancer, as they can deliver large doses of drugs in solid 
or liquid form. For example, Ong et al69 developed a micro-
device consisting of a micromachined polysulfone reservoir 
and cap. The reservoir was drug-impermeable and consisted 
of a cylinder of 2 mm in diameter and 2 mm in height. The 
cap of the device was machined with pores of 300 µm in 
diameter through which the encapsulated drug could pass. 
Drug release from this polysulfone microdevice was linear 
and highly dependent on the number of holes in the cap: the 
greater the number of holes, the faster the release of the drug. 
Grayson et al70 produced another form of microreservoir 
consisting of a polymeric microchip device. These micro-
chips were 1.2 cm in diameter and 480–560 µm thick, and 
they had 36 reservoirs, each of which could be loaded with a 
different substance. These devices were made of poly(l-lactic 
acid) (PLLA) and each reservoir was covered with a PLGA 
membrane. By altering the molecular mass of the PLGA 
membrane, drug delivery systems could be developed with 
the potential to release pulses of different drugs at different 
times after implantation in a patient.
Nanocarriers
The use of nanocarriers for cancer treatment has been 
described in a number of studies.71–74 Nanocarriers are par-
ticles with at least one dimension in the 1–1,000 nm size 
range. They can be used for the local or systemic delivery 
of various agents, such as drugs, radionuclides, imaging 
agents, and bioactive compounds (siRNA or DNA). These 
agents can be entrapped in, adsorbed onto, or chemically 
bonded to the nanocarrier surface. Nanocarriers protect the 
active agents against enzymatic and hydrolytic degradation, 
improve their solubility and pharmacokinetic parameters, 
and control their release. Their composition, size, and other 
surface characteristics can easily be modified to bypass physi-
ological barriers, including the BBB. Various nanocarriers 
are available: polymeric, lipid-based, and inorganic.
Two types of nanocarriers have been developed for anti-
angiogenic therapy: 1) nanocarriers carrying antiangiogenic 
factors, and 2) vascular-targeted nanocarriers generated by 
the conjugation of nanocarriers to molecules that bind to 
angiogenesis-related receptors. These nanocarriers can be 
used to detect and visualize angiogenesis and/or to direct 
chemotherapy, phototherapy, or gene therapy to the tumor 
vasculature. In this review, we present only the nanocarriers 
used for antiangiogenic factor delivery.
An entire arsenal of nanocarriers carrying antiangiogenic 
factors has been produced, but few have been tested in 
orthotopic GB models. We identified three studies reporting 
the use of polyplexes for the delivery of genes encoding 
antiangiogenic factors39,75,76 in addition to the work of our 
laboratory on the use of LNCs for SFN delivery45 (Table 1; 
Figure 4). Ohlfest et al39 produced polyplexes encoding two 
antiangiogenic proteins, sFlt-1 and statin-AE. They showed 
that the CED of these polyplexes in U87MG tumor-bearing 
mice led to strong antitumor activity characterized by a 
decrease in tumor vessel density, the inhibition of tumor 
growth, and tumor elimination in up to 50% of mice (Table 
1). In other studies, polyplexes encoding IL-12 and vastatin 
or endostain were produced.75,76 The intratumoral injection 
of these antiangiogenic polyplexes in GB-bearing mice led 
to a significant increase in survival relative to untreated 
mice, which was increased still further by their combina-
tion with chemotherapy agents (BCNU or TMZ) (Table 1). 
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Our laboratory recently produced LNCs for SFN 
encapsulation, because this multikinase inhibitor is poorly 
soluble in water, which limits its use for local or systemic 
administration.45 We showed that the CED of SFN-LNCs in 
the orthotopic U87MG GB model decreased the proportion 
of proliferating cells in the tumor and induced early tumor 
vascular normalization, characterized by an increase in tumor 
blood flow and a decrease in tumor vessel area (Table 1). This 
vascular normalization may provide a window of opportunity 
for enhancing the efficacy of chemotherapy or radiotherapy.
Cellular vehicles
Cellular vehicles, including microencapsulated cells and 
adult stem cells, have been used to deliver antiangiogenic 
factors in orthotopic GB models (Table 1; Figure 4).
Microencapsulated cells
Living cells are encapsulated in polymeric microspheres or 
microcapsules for many biomedical and biotechnological 
applications, including local and long-term drug delivery 
and regenerative medicine.77–81 The microencapsulation of 
cells allows the free exchange of nutrients and waste while 
excluding agents of the immune system, thereby promoting 
the survival of the transplanted cells. It also permits the 
release of therapeutic cell products. A number of different 
biomaterials, such as alginate, hyaluronic acid, agarose, and 
other polymers, have been used for encapsulation.
Read et al82 encapsulated human fetal kidney 293 cells 
transfected with a pCEPPu episomal expression vector 
encoding human endostatin in sodium alginate microcap-
sules. They showed that encapsulated endostatin-producing 
293 cells remained viable for at least 4 months after intra-
cerebral implantation, and that they continued to produce 
endostatin after encapsulation and implantation. The spatial 
distribution of endostatin in the brain/tumor tissue was 
determined, and this molecule was detected at 1–1.7 mm 
from the bioreactors, with some more distant deposits 
(4–6 mm). It was also found in the cerebrospinal fluid. Rats 
receiving transplants of BT4C glioma cells together with 
encapsulated endostatin-producing 293 cells survived for 
84% longer than controls. The endostatin released from the 
microcapsules triggered apoptosis, hypoxia, and the forma-
tion of large necrotic avascular areas in 77% of the treated 
tumors, whereas these features were not observed in any of 
the controls. The apparent biological effects of endostatin 
were observed for tumors inoculated 1 week before or at the 
same time as bioreactor implantation. However, no signifi-
cant effect on animal survival was observed when animals 
received the treatment 1 week after tumor inoculation. 
Intravital multifluorescence microscopy showed that the 
endostatin released from the capsules decreased not only total 
vascular density, but also the functionality and diameter of 
blood vessels and tumor cell invasion.83,84
Efforts are currently being made to encapsulate cell 
lines producing different recombinant proteins capable of 
interfering with tumor growth and progression. In this way, 
a “library” of encapsulated cells can be generated, with the 
aim of tailoring local therapy to specific biological param-
eters regulating tumor growth. In parallel, optimization is 
required to achieve sufficient biosafety and biocompatibility 
for clinical approval.
Adult stem cells
The particular tropism for brain tumors displayed by stem 
cells, such as neural stem cells (NSCs) and MSCs, has led 
these cells to being considered potential candidate treatment 
delivery agents.85 Adult NSCs are found within the subven-
tricular zone and the hippocampal dentate gyri and give rise 
to neurons and glia. The preparation of sufficient numbers 
of autologous NSCs for clinical applications remains tech-
nically challenging. Fetal brain, adult allogeneic brain, and 
embryonic stem cells are therefore all currently being consid-
ered as possible substitutes for autologous NSCs. MSCs are 
multipotent cells capable of differentiating into multiple cell 
types, including chondrocytes, adipocytes, and osteoblasts. 
They were originally isolated from bone marrow, but can 
be obtained from many other sources, including peripheral 
blood, umbilical cord blood, and adipose tissue. MSCs are 
an attractive alternative to NSCs because they are easy to 
propagate in vitro and because the implantation of autolo-
gous MSCs in patients with GB entails fewer ethical prob-
lems. In most studies of antiangiogenic therapy with NSCs or 
MSCs, these cells are genetically modified to express IL-12, 
endostatin, IFN-α, TSP-1, or PEX and are delivered directly 
to the brain tumor.86–94 The treatment of intracranial gliomas 
with these engineered cells has been shown to inhibit tumor 
progression, and/or to increase survival in mice (Table 1). 
Furthermore, the simultaneous delivery of antiangiogenic 
factors (endostatin or TSP-1) and chemotherapy factors 
(a secretable form of carboxylesterase 2 [sCE2] along with 
CPT-11 treatment or a secretable variant of tumor necrosis 
factor-related apoptosis-inducing ligand [TRAIL]) by MCSs 
yielded the stronger antitumor responses86,94 (Table 1). 
We recently showed that MSCs can deliver the chemother-
apy drug ferrociphenol and the antiangiogenic TKI SFN to 
brain tumors without the need for genetic modification.95,96 
MSCs can be primed in vitro with SFN, with no effect on 
viability, and can release 60% of the drug with which they 
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are loaded. The cytostatic activity of the released SFN was 
entirely conserved, significantly decreasing the survival 
of human U87MG GB cells and endothelial cells in vitro. 
We investigated the in vivo effect of SFN-primed MSCs on 
the orthotopic U87MG GB model, following their intranasal 
administration. Unlike direct intracranial delivery, intranasal 
delivery is noninvasive, making the repeated administra-
tion of treatment possible. Furthermore, this delivery route 
appears to be a promising alternative to intravenous injec-
tions of MSCs, which generally lead to the entrapment and 
elimination of MSCs in peripheral organs and a risk of 
vascular and pulmonary embolization.97,98 The treatment of 
U87MG tumor-bearing mice with two intranasal administra-
tions of SFN-primed MSCs 4 days apart has been shown to 
result in lower levels of tumor angiogenesis than the injec-
tion of unprimed MSCs or SFN alone, but with no effect on 
tumor volume. The absence of an effect on tumor volume 
is probably due to the use of too low a dose of SFN-primed 
MSCs. The intranasal administration of larger numbers of 
SFN-primed MSCs may be required for an effect on U87MG 
growth. No clinical trial has yet been performed to assess 
the use of MSCs as cellular vehicles for GB therapy. One 
reason for this may be the widespread use of viral vectors 
for the production of therapeutic MSCs. The use of viruses 
is associated with a number of disadvantages, including risks 
of toxicity, immunogenicity, insertional mutagenesis, and 
high manufacturing costs.99 Another possible reason is the 
conflicting data published concerning the use of MSCs in 
cell-based therapies. The role of MSCs in cancer progres-
sion remains a matter of heated debate, but the number of 
studies reporting a role for these cells in cancer progression 
is steadily increasing.100–103 Consistent with the findings of 
these studies, we found that the intranasal administration of 
unprimed MSCs induced a significant increase in the number 
of small vessels in the U87MG tumor, which was abolished 
when MSCs were primed with SFN. Several studies have 
indicated that MSCs promote angiogenesis by secreting 
angiogenic factors, such as VEGF, releasing exosomes, 
recruiting endothelial progenitors, and/or transdifferentiat-
ing into endothelial cells.104,105 Our previous studies96,106 
showed no effect of unprimed MSCs on tumor volume or 
the proportion of Ki67+ tumor cells in the human U87MG 
GB model, but MSCs have been reported to facilitate tumor 
growth by secreting various anti-inflammatory cytokines 
and proangiogenic factors.100–103 Furthermore, MSCs can 
differentiate into cancer-associated fibroblasts (CAFs), 
which have been detected in the stroma of carcinomas 
and are known to promote tumor growth.100 In the GB 
peritumoral environment, we identified MSC-like cells that 
we named GB-associated stromal cells (GASCs), which 
had phenotypic and functional properties in common with 
MSCs and CAFs.107–109 Like unprimed MSCs, their injection 
into intracranial U87MG tumors had no effect on tumor 
volume but promoted angiogenesis, increasing the number 
of small intratumoral vessels.108 In other studies, MSC-like 
cells were isolated from the GB tumor core and shown 
to increase angiogenesis, GB cell proliferation, and inva-
sion.110–114 Consistent with these findings, the percentage of 
GB-associated MSC-like cells has recently been shown to 
be inversely correlated with overall survival, indicating a 
role for these cells in promoting the aggressive behavior of 
GB.115,116 All these data raise questions about the suitability 
of MSCs as cellular vehicles for the delivery of therapeutic 
molecules in the context of GB. Even if MSCs are able to 
deliver the therapeutic agent to the tumor, their protumori-
genic and proangiogenic properties may limit the effect of 
this agent. We need to find ways of guaranteeing the safety 
of this cellular vector for clinical use. One possibility would 
be to use a suicide gene or a small molecule to induce senes-
cence in the MSCs after drug delivery. EPCs, which display 
specific homing to angiogenic sites in vivo, are a potentially 
attractive alternative to MSCs, but the therapeutic effect of 
modified EPCs in orthotopic GB models has never been 
investigated.117–121
Conclusion
Various nonviral delivery methods, including CED devices, 
implantable polymer devices, nanocarriers, and cellular 
vehicles, have been developed to improve the efficacy of 
GB treatment with antiangiogenic factors. All these delivery 
methods, tested in orthotopic GB models, were found to be 
effective, but only CED devices have been translated into 
clinical practice. Studies showing clear-cut advantages 
of one particular type of antiangiogenic factor delivery 
method over another in a representative GB model would 
facilitate the translation of such methods from the bench 
to the clinic (Figure 5). For such studies, there is an urgent 
need to identify the angiogenesis inhibitors giving the 
best response in preclinical studies and to focus on cheap, 
easily produced biocompatible nonviral delivery methods 
that could be rapidly transferred into clinical practice. The 
delivery route is also a major matter of concern that must 
be addressed. CED devices, implantable polymer devices, 
and microencapsulated cells are local delivery methods. 
They have the advantage of providing higher concentrations 
of antiangiogenic factors in the tumor than systemic deliv-
ery methods. However, they require intracranial surgery, 
which is not compatible with the use of factors for which 
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a regime involving repeated injections is required for an 
effect on the tumor vasculature. In this case, nanocarriers 
or adult stem cells, which can be administered systemi-
cally, should be favored. Furthermore, it should also be 
borne in mind that angiogenesis inhibitor therapy alone 
is not sufficient to counteract the growth of GB, given the 
aggressiveness of this type of brain cancer and its resistance 
to various treatments. Further studies will therefore also 
be required to evaluate and optimize dosing schedules, for 
the development of effective combinations of the selected 
antiangiogenic factor delivery method with other treatments, 
such as chemotherapy, radiotherapy, and phototherapy. All 
these studies will take time but are necessary to ensure that 
the selected antiangiogenic factor delivery method is of 
unequivocal and meaningful clinical benefit to GB patients 
in the future. Particular attention should be paid to the 
emerging vascular-targeted nanotheranostic devices consist-
ing of multifunctional nanocarriers for both diagnosis and 
the delivery of therapeutic agents to the tumor vasculature.122 
The results obtained with these systems in preclinical mod-
els of GB should be monitored to determine whether they 
are likely to be more effective than antiangiogenic factor 
delivery methods (Figure 5).
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